1 THE ROLE OF COVARIATES IN CLINICAL TRIALS ANALYSES Ralph B. D’Agostino, Sr., PhD Boston University FDA ODAC March 13, 2006.

Slides:



Advertisements
Similar presentations
High Resolution studies
Advertisements

A Spreadsheet for Analysis of Straightforward Controlled Trials
The Application of Propensity Score Analysis to Non-randomized Medical Device Clinical Studies: A Regulatory Perspective Lilly Yue, Ph.D.* CDRH, FDA,
COMPUTER INTENSIVE AND RE-RANDOMIZATION TESTS IN CLINICAL TRIALS Thomas Hammerstrom, Ph.D. USFDA, Division of Biometrics The opinions expressed are those.
Survival Analysis In many medical studies, the primary endpoint is time until an event occurs (e.g. death, remission) Data are typically subject to censoring.
Study Size Planning for Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare Research and Quality (AHRQ)
Statistical Analysis and Data Interpretation What is significant for the athlete, the statistician and team doctor? important Will Hopkins
Introduction to Survival Analysis October 19, 2004 Brian F. Gage, MD, MSc with thanks to Bing Ho, MD, MPH Division of General Medical Sciences.
Estimation of Sample Size
ODAC May 3, Subgroup Analyses in Clinical Trials Stephen L George, PhD Department of Biostatistics and Bioinformatics Duke University Medical Center.
Estimation and Reporting of Heterogeneity of Treatment Effects in Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2009.
1.A 33 year old female patient admitted to the ICU with confirmed pulmonary embolism. It was noted that she had elevated serum troponin level. Does this.
Common Problems in Writing Statistical Plan of Clinical Trial Protocol Liying XU CCTER CUHK.
Chapter 51 Experiments, Good and Bad. Chapter 52 Experimentation u An experiment is the process of subjecting experimental units to treatments and observing.
Chapter 11 Survival Analysis Part 2. 2 Survival Analysis and Regression Combine lots of information Combine lots of information Look at several variables.
Sample Size Determination
Sample Size Determination Ziad Taib March 7, 2014.
Assessing Survival: Cox Proportional Hazards Model Peter T. Donnan Professor of Epidemiology and Biostatistics Statistics for Health Research.
12/10/02Harry Bushar1 Computerized Thermal Imaging Breast Cancer System 2100 (CTI BCS2100) Radiological Devices Advisory Panel December 10, 2002 Statistical.
Are the results valid? Was the validity of the included studies appraised?
Multiple Choice Questions for discussion
Advanced Statistics for Interventional Cardiologists.
Gil Harari Statistical considerations in clinical trials
Intergroup trial CALGB 80101
Dr Laura Bonnett Department of Biostatistics. UNDERSTANDING SURVIVAL ANALYSIS.
Journal Club Hallie Lee PharmD Candidate 2013 Mercer University COPHS PHA 618 Geriatrics-Continuous Care Multivitamins in the Prevention of Cardiovascular.
Skull Base Chordoma and Chondrosarcoma: Changes in National Radiotherapy Patterns and Survival Outcomes Henry S. Park, MD, MPH; Kenneth B. Roberts, MD;
Biostatistics Case Studies Peter D. Christenson Biostatistician Session 5: Analysis Issues in Large Observational Studies.
Introduction To Biological Research. Step-by-step analysis of biological data The statistical analysis of a biological experiment may be broken down into.
Education Research 250:205 Writing Chapter 3. Objectives Subjects Instrumentation Procedures Experimental Design Statistical Analysis  Displaying data.
Assessing Survival: Cox Proportional Hazards Model
Consumer behavior studies1 CONSUMER BEHAVIOR STUDIES STATISTICAL ISSUES Ralph B. D’Agostino, Sr. Boston University Harvard Clinical Research Institute.
Bayesian Analysis and Applications of A Cure Rate Model.
1 Statistical Review Dr. Shan Sun-Mitchell. 2 ENT Primary endpoint: Time to treatment failure by day 50 Placebo BDP Patients randomized Number.
Tony Panzarella Princess Margaret Hospital / University of Toronto.
1 1 Using Marginal Structural Model to Estimate and Adjust for Causal Effect of Post- discontinuation Chemotherapy on Survival in Cancer Trials Y. Wang,
1 OTC-TFM Monograph: Statistical Issues of Study Design and Analyses Thamban Valappil, Ph.D. Mathematical Statistician OPSS/OB/DBIII Nonprescription Drugs.
Lecture 9: Analysis of intervention studies Randomized trial - categorical outcome Measures of risk: –incidence rate of an adverse event (death, etc) It.
Three Statistical Issues (1) Observational Study (2) Multiple Comparisons (3) Censoring Definitions.
1 Lecture 6: Descriptive follow-up studies Natural history of disease and prognosis Survival analysis: Kaplan-Meier survival curves Cox proportional hazards.
1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.
Survival Analysis approach in evaluating the efficacy of ARV treatment in HIV patients at the Dr GM Hospital in Tshwane, GP of S. Africa Marcus Motshwane.
Statistical Review of P Acorn’s CorCap Cardiac Support Device
C-1 Efficacy of the Combination: Meta-Analyses Donald A. Berry, Ph.D. Frank T. McGraw Memorial Chair of Cancer Research University of Texas M.D. Anderson.
1 BLA Sipuleucel-T (APC-8015) FDA Statistical Review and Findings Bo-Guang Zhen, PhD Statistical Reviewer, OBE, CBER March 29, 2007 Cellular, Tissue.
CV-1 Trial 709 The ISEL Study (IRESSA ® Survival Evaluation in Lung Cancer) Summary of Data as of December 16, 2004 Kevin Carroll, MSc Summary of Data.
Statistical Comments on Retrospective Analysis Girish Aras, Ph.D. Jonathan Ma, Ph.D. Center for Drug Evaluation and Research, FDA.
1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.
THE ROLE OF SUBGROUPS IN CLINICAL TRIALS Ralph B. D’Agostino, Sr., PhD Boston University September 13, 2005.
Rerandomization to Improve Covariate Balance in Randomized Experiments Kari Lock Harvard Statistics Advisor: Don Rubin 4/28/11.
SNDA # GLIADEL® WAFER (Polifeprosan 20 with Carmustine Implant) APPLICANT: GUILFORD PHARMACEUTICALS ODAC: December 6, 2001 Medical Reviewer: Alla.
Zometa for Prostate Cancer Bone Metastases Protocol 039 Amna Ibrahim, M.D. Oncology Drug Products FDA.
Additional Regression techniques Scott Harris October 2009.
Practical Solutions Additional Regression techniques.
J Clin Oncol 30: R2 윤경한 / Prof. 김시영 Huan Jin, Dongsheng Tu, Naiqing Zhao, Lois E. Shepherd, and Paul E. Goss.
Methods and Statistical analysis. A brief presentation. Markos Kashiouris, M.D.
BIOST 513 Discussion Section - Week 10
The Importance of Adequately Powered Studies
Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: Focus on trabectedin  Andrés Poveda, Isabelle Ray-Coquard, Ignacio Romero,
How many study subjects are required ? (Estimation of Sample size) By Dr.Shaik Shaffi Ahamed Associate Professor Dept. of Family & Community Medicine.
Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: Influence of Prognostic Factors of Survival J Tabernero,
Figure 2. A consort diagram showing the flowchart of the trial
Mark Rothmann U.S. Food and Drug Administration September 14, 2018
Narrative Reviews Limitations: Subjectivity inherent:
Evidence Based Practice
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,
Helen Barraclough, MSc, Ramaswamy Govindan, MD 
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
Stratified Covariate Balancing Using R
Presentation transcript:

1 THE ROLE OF COVARIATES IN CLINICAL TRIALS ANALYSES Ralph B. D’Agostino, Sr., PhD Boston University FDA ODAC March 13, 2006

2 OUTLINE Setting of Randomized Clinical Trials General issues for the use of covariates in primary analyses Clinical trial scenarios for covariate analysis (including secondary and third level analyses) –From good to not-so-good practices Closing Comments

3 SETTING OF RANDOMIZED CLINICAL TRIAL Two treatments to be compared Subjects randomized to treatments Desire to test differences of treatments on a primary end point (e.g., time to death) Baseline data (covariates) collected on subject –Age, Gender, Severity, Location of Cancer, Clinic Site

4 GENERAL ISSUES FOR USE OF COVARIATES IN PRIMARY ANALYSIS 1.Randomization is assumed adequate to balance treatment groups and covariates not used in primary analysis 2.Covariates used to reduce variability (to increase precision) 3.Randomization may not balance treatment groups. Imbalances identified and these covariates put into primary analyses.

5 GOOD PRACTICES The following scenarios have the feature of a careful analysis plan stated clearly in the protocol or statistical analysis plan (SAP) that was developed before data set is locked

6 CLINICAL TRIAL SCENARIOS INCLUDING SECONDARY &THIRD LEVEL 1.PRIMARY ANALYSIS: RANDOMIZATION IS ASSUMED ADEQUATE TO BALANCE TREATMENT GROUPS AND COVARIATES NOT USED IN PRIMARY ANALYSIS A statistical test is performed comparing directly the two treatments with a statistical test that does not include covariate (e,g., log rank test on time to death (survival) analysis). This is the primary analysis.

7 GOOD: T 1 better than T 2 Events Plots over Study Time TREATMENT 1 TREATMENT 2 - Time from randomization in years

8 1. NO COVARIATES USED IN PRIMARY ANALYSIS SECONDARY LEVEL ANALYSIS examines covariates and subgroups to see consistency and sensitivity of overall results Covariate analysis. In survival analysis extend log rank test to Cox regression that adds one or more covariates at a time (e.g., treatment and age to examine age effect in presence of treatment)

Overall Gender Males females Age < 65 >65 Years with Condition Hazard Ratio yes no Location X NO YES 1 better 2 better Special subgroup Treatment really works

10 1. NO COVARIATES USED IN PRIMARY ANALYSIS THIRD LEVEL ANALYSIS Build a multivariate model that includes all important covariates and treatment This allows us to demonstrate consistency across variables and build a multivariate model that includes effect of treatment. It also can identify important subsets.

11 CLINICAL TRIAL SCENARIOS INCLUDING SECONDARY &THIRD LEVEL 2. PRIMARY ANALYSIS: COVARIATES USED TO REDUCE VARIABILITY (TO INCREASE PRECISION) A statistical test is performed comparing directly the two treatments with a statistical test that adjusts for preselected covariates (e,g., Cox regression on time to death (survival) analysis that adjusts for age or severity). This is the primary analysis.

12 2. PRE-SELECTED COVARIATES USED TO REDUCE VARIABILITY Example: Weight reduction study use baseline weight Example: Age, disease severity and location of cancer may be a priori selected for primary analysis. These variables may also have been used in randomization for stratification

13 2. PRE-SELECTED COVARIATES USED TO REDUCE VARIABILITY SECONDARY AND THIRD LEVEL ANALYSES ARE THE SAME AS BEFORE EXCEPT A-PRIORI SELECTED COVARIATES NEED TO BE CONSIDERED

14 CLINICAL TRIAL SCENARIOS INCLUDING SECONDARY &THIRD LEVEL 3.PRIMARY ANALYSIS RANDOMIZATION MAY NOT BALANCE TREATMENT GROUPS. IMBALANCES IDENTIFIED AND THESE COVARIATES PUT INTO PRIMARY ANALYSES Potential covariates on which imbalances may exist are identified in protocol and tested for significance and then put into primary analysis (e.g., severity, gender, age) if significant Control of alpha error rates should be considered

15 3. COVARIATES FOR WHICH IMBALANCES IDENTIFIED FIRST SECONDARY AND THIRD LEVEL ANALYSES ARE THE SAME AS BEFORE EXCEPT IDENTIFIED IMBALANCED COVARIATES NEED TO BE CONSIDERED

16 BAD PRACTICE The following has the feature that the PRIMARY ANALYSIS FAILED and then exploratory analyses (stated as planned or not) undertaken to identify covariates and determine treatment effects

17 PROBLEMS 1.Once primary analysis fails the alpha error has been used. There is no way of retrieving it with a secondary or exploratory analysis 2.The variability often associated with this practice is often so large that it adds nothing beyond original failed primary analysis

18 OVERALL TEST IS NOT SIGNIFICANT TECHNICALLY YOU CANNOT GO BEYOND THIS WITH ANY STATISTICAL STATEMENTS USEFUL TO LOOK AT COVARIATES AND SUBSETS AS EXPLORATORY ANALYSIS (NOT EVEN APPROPRIATE TO CALL IT A SECONDARY ANALYSIS)

19 PROBLEM: T1 not better Events Plots over Study Time TREATMENT 1 TREATMENT 2 - Time from randomization in years

20 SEARCH FOR COVARIATES Age ( > = 65 years vs < 65 years) ECOG Performance (1 or 2 vs 0) Tumor size (> 18.7 cm 2 or not) Disease state

21 ECOG Status EFFECT Status = 0 1 or 2 - Time from randomization in years

22 PROCEDURE Can look at covariates one at a time related to outcome variable or in conjunction with treatment In the end a multivariate analysis is done with covariates and treatment in model

23 TYPICAL RESULTS PRIMARY ANALYSIS –HR = 0.98,.95 CI (0.78 TO 1.24) COVARIATE ANALYSIS AFTER FAILED PRIMARY ANALYSIS –HR = 0.86,.95 CI (0.67 TO 1.10) TWO HRs NOT SIGNIFICANTLY DIFFERENT TWO CONFIDENCE INTERVALS OVERLAP (NO DIFFERENCE)

24 ANOTHER TYPICAL RESULT Primary analysis – HR = 0.98 (.78 to 1.24) One set of covariates –HR = 0.68 (.50 to.94) Another set of covariates –HR = 0.89 (.63 to 1.05) –WHAT DO WE BELIEVE?

25 CONCLUSION: STATISTICAL PROPERTIES OF ANALYSES If Primary analysis is significance Then as secondary analyses we can examine covariates and control error rates (that is, can control chance of identifying falsely significant covariates). Looking for joint relation of treatment and covariates to end point If number of covariates is unspecified, then analysis is exploratory even here

26 Conclusion: Statistical properties of analyses (continue) If Primary analysis is not significant, then we cannot control error rate (falsely identifying significant covariates and “saving” or improving treatment differences). We have used “alpha” on overall test Often do not get clarity from later analyses

27 Closing Comments Careful analysis plans can be stated for dealing with covariates. Error rates (level of significance) can be controlled even for considering covariates if structure of statistical approach is clearly stated. We must not confuse statistical procedures with covariates stated in a pre-specified manner from covariate analysis that follow after failed primary analysis and have no way of controlling statistical error rates